Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol. Issue 9 (21st September 2022)

• Record Type: Journal Article
• Authors: Dasgupta, Kaberi; Boulé, Normand; Henson, Joseph; Chevalier, Stéphanie; Redman, Emma; Chan, Deborah; McCarthy, Matthew; Champagne, Julia; Arsenyadis, Frank; Rees, Jordan; Da Costa, Deborah; Gregg, Edward; Yeung, Roseanne; Hadjiconstantinou, Michelle; Dattani, Abhishek; Friedrich, Matthias G; Khunti, Kamlesh; Rahme, Elham; Fortier, Isabel; Prado, Carla M; Sherman, Mark; Thompson, Richard B; Davies, Melanie J; McCann, Gerry P; Yates, Thomas
• Is Part Of: BMJ open. Volume 12:Issue 9(2022)
• Publication Date: 2022-09-21
• Subjects: DIABETES & ENDOCRINOLOGY -- CARDIOLOGY -- NUTRITION & DIETETICS; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-063888
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Type 2 diabetes mellitus (T2DM) onset before 40 years of age has a magnified lifetime risk of cardiovascular disease. Diastolic dysfunction is its earliest cardiac manifestation. Low energy diets incorporating meal replacement products can induce diabetes remission, but do not lead to improved diastolic function, unlike supervised exercise interventions. We are examining the impact of a combined low energy diet and supervised exercise intervention on T2DM remission, with peak early diastolic strain rate, a sensitive MRI-based measure, as a key secondary outcome. Methods and analysis: This prospective, randomised, two-arm, open-label, blinded-endpoint efficacy trial is being conducted in Montreal, Edmonton and Leicester. We are enrolling 100 persons 18–45 years of age within 6 years' T2DM diagnosis, not on insulin therapy, and with obesity. During the intensive phase (12 weeks), active intervention participants adopt an 800–900 kcal/day low energy diet combining meal replacement products with some food, and receive supervised exercise training (aerobic and resistance), three times weekly. The maintenance phase (12 weeks) focuses on sustaining any weight loss and exercise practices achieved during the intensive phase; products and exercise supervision are tapered but reinstituted, as applicable, with weight regain and/or exercise reduction. The control arm receives standard care. The primary outcome is T2DM remission, (haemoglobin A1c of less than 6.5% at 24 weeks, without use of glucose-lowering medications during maintenance). Analysis of remission will be by intention to treat with stratified Fisher's exact test statistics. Ethics and dissemination: The trial is approved in Leicester (East Midlands – Nottingham Research Ethics Committee (21/EM/0026)), Montreal (McGill University Health Centre Research Ethics Board (RESET for remission/2021-7148)) and Edmonton (University of Alberta Health Research Ethics Board (Pro00101088). Findings will be shared widely (publications, presentations, press releases, social media platforms) and will inform an effectiveness trial. Trial registration number: ISRCTN15487120 .